Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Liabilities and Shareholders Equity (2023 - 2026)

Alto Neuroscience has reported Liabilities and Shareholders Equity over the past 4 years, most recently at $276.3 million for Q1 2026.

  • Quarterly results put Liabilities and Shareholders Equity at $276.3 million for Q1 2026, up 60.7% from a year ago — trailing twelve months through Mar 2026 was $765.8 million (up 3.71% YoY), and the annual figure for FY2025 was $184.7 million, up 4.03%.
  • Liabilities and Shareholders Equity reached $276.3 million in Q1 2026 per ANRO's latest filing, up from $184.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $276.3 million in Q1 2026 and bottomed at $86.6 million in Q4 2023.
  • Median Liabilities and Shareholders Equity over the past 4 years was $181.1 million (2024), compared with a mean of $180.1 million.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 104.95% in 2024 before it decreased 23.28% in 2025.
  • Over 4 years, Liabilities and Shareholders Equity stood at $86.6 million in 2023, then soared by 104.95% to $177.5 million in 2024, then increased by 4.03% to $184.7 million in 2025, then skyrocketed by 49.58% to $276.3 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for ANRO at $276.3 million in Q1 2026, $184.7 million in Q4 2025, and $147.0 million in Q3 2025.